Nerve cut may supercharge tongue cancer treatment
NCT ID NCT07346807
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase II trial tests whether surgically cutting the lingual nerve (which controls tongue sensation) can make chemoimmunotherapy work better for people with advanced tongue cancer. 69 adults with stage T3/T4 tongue cancer will receive the nerve cut along with two cycles of tislelizumab, cisplatin, and nab-paclitaxel before standard surgery. The main goal is to see if this combination improves tumor response before surgery.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
lingual nerve disruption (surgical nerve cut), tislelizumab (immunotherapy), albumin-bound paclitaxel and cisplatin (chemotherapy)
What this could lead to
If it works, this could point toward a way to make standard chemoimmunotherapy more effective for advanced tongue cancer before surgery.
What could go wrong
This is a small, early-phase trial with only 69 people and no comparison group. The nerve-cutting procedure is experimental and may cause permanent numbness or other side effects without improving outcomes.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TONGUE SQUAMOUS CELL CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Zhongshan Hospital Fudan University
Shanghai, Shanghai Municipality, 200032, China
Contact Phone: •••-•••-•••• Email: •••••@•••••